| 黄滟凌,罗远湘,陈 娟,刘洪科,李林珊.雷珠单抗联合复方血栓通胶囊对年龄相关性黄斑变性患者血液流变学和血清VEGF、PDGF的影响[J].现代生物医学进展英文版,2022,(8):1582-1585. |
| 雷珠单抗联合复方血栓通胶囊对年龄相关性黄斑变性患者血液流变学和血清VEGF、PDGF的影响 |
| Effects of Ranibizumab Combined with Fufang Xueshuantong Capsule on Hemorheology, Serum VEGF and PDGF in Patients with Age-Related Macular Degeneration |
| Received:September 06, 2021 Revised:September 29, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.08.038 |
| 中文关键词: 雷珠单抗 复方血栓通胶囊 年龄相关性黄斑变性 血液流变学 VEGF PDGF |
| 英文关键词: Ranibizumab Fufang Xueshuantong capsule Age-related macular degeneration Hemorheology VEGF PDGF |
| 基金项目:四川省卫生和计划生育委员会科研项目（170137） |
|
| Hits: 678 |
| Download times: 346 |
| 中文摘要: |
| 摘要 目的：观察雷珠单抗联合复方血栓通胶囊对年龄相关性黄斑变性（AMD）患者血液流变学和血清血管内皮生长因子（VEGF）、血小板衍生生长因子（PDGF）的影响。方法：选取我院2019年6月~2021年1月收治的AMD患者60例（96眼），按照随机数字表法分别为对照组（n=30，46眼）和实验组（n=30，50眼），对照组给予雷珠单抗治疗，实验组给予雷珠单抗联合复方血栓通胶囊治疗，对比两组眼部相关指标、血液流变学指标和血清VEGF、PDGF水平变化情况，观察两组治疗期间不良反应发生情况。结果：实验组治疗3个月后眼内压（IOP）、黄斑中央区厚度（CMT）、脉络新生血管（CNV）面积低于对照组，视力高于对照组（P<0.05）。实验组治疗3个月后全血低切/中切/高切黏度、血浆黏度低于对照组（P<0.05）。实验组治疗3个月后血清VEGF、PDGF水平低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：雷珠单抗联合复方血栓通胶囊可改善AMD临床症状，促进视力恢复，其作用机制可能与调节机体血液流变学、血清VEGF、PDGF水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of ranibizumab combined with Fufang Xueshuantong capsule on hemorheology, serum vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) in patients with age-related macular degeneration (AMD). Methods: 60 patients (96 eyes) with AMD who were treated in our hospital from June 2019 to January 2021 were selected, and they were randomly divided into control group (n=30, 46 eyes) and experimental group (n=30, 50 eyes). The control group was treated with ranibizumab, and the experimental group was treated with ranibizumab combined with Fufang Xueshuantong capsule. Eye related indexes, hemorheology indexes, serum VEGF and PDGF levels were compared between the two groups, and the occurrence of adverse reactions during treatment was observed. Results: The intraocular pressure (IOP), central macular thickness (CMT) and choroidal neovascularization area (CNV) of the experimental group at 3 months after treatment were lower than those of the control group, and the visual acuity was higher than that of the control group(P<0.05). 3 months after treatment, the whole blood low/medium/high shear viscosity and plasma viscosity of the experimental group were lower than those of the control group (P<0.05). 3 months after treatment, the levels of serum VEGF and PDGF of the experimental group were lower than those of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Ranibizumab combined with Fufang Xueshuantong capsule can improve the clinical symptoms of AMD, and promote the recovery of vision, and the mechanism may be related to the regulation of hemorheology, serum VEGF and PDGF levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
